Becton Dickinson and Company (BDX)vsHarvard Bioscience Inc (HBIO)
BDX
Becton Dickinson and Company
$195.16
+0.07%
HEALTHCARE · Cap: $52.23B
HBIO
Harvard Bioscience Inc
$8.42
+0.84%
HEALTHCARE · Cap: $37.97M
Smart Verdict
WallStSmart Research — data-driven comparison
Becton Dickinson and Company generates 25506% more annual revenue ($22.48B vs $87.81M). BDX leads profitability with a 4.2% profit margin vs -11.9%. BDX appears more attractively valued with a PEG of 1.11. BDX earns a higher WallStSmart Score of 52/100 (C-).
BDX
Buy52
out of 100
Grade: C-
HBIO
Hold38
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+10.7%
Fair Value
$202.19
Current Price
$195.16
$7.03 discount
Intrinsic value data unavailable for HBIO.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Large-cap with strong market position
Reasonable price relative to book value
No standout strengths identified
Areas to Watch
ROE of 3.9% — below average capital efficiency
4.2% margin — thin
Premium valuation, high expectations priced in
Earnings declined 31.4%
Smaller company, higher risk/reward
Weak financial health signals
ROE of -147.1% — below average capital efficiency
Earnings declined 80.3%
Comparative Analysis Report
WallStSmart ResearchBull Case : BDX
The strongest argument for BDX centers on Market Cap, Price/Book. PEG of 1.11 suggests the stock is reasonably priced for its growth.
Bull Case : HBIO
Revenue growth of 11.1% demonstrates continued momentum. PEG of 1.31 suggests the stock is reasonably priced for its growth.
Bear Case : BDX
The primary concerns for BDX are Return on Equity, Profit Margin, P/E Ratio. A P/E of 44.6x leaves little room for execution misses. Thin 4.2% margins leave little buffer for downturns.
Bear Case : HBIO
The primary concerns for HBIO are Market Cap, Piotroski F-Score, Return on Equity. Debt-to-equity of 5.96 is elevated, increasing financial risk.
Key Dynamics to Monitor
BDX profiles as a value stock while HBIO is a turnaround play — different risk/reward profiles.
HBIO carries more volatility with a beta of 1.51 — expect wider price swings.
HBIO is growing revenue faster at 11.1% — sustainability is the question.
BDX generates stronger free cash flow (509M), providing more financial flexibility.
Bottom Line
BDX scores higher overall (52/100 vs 38/100). Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Becton Dickinson and Company
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Becton, Dickinson and Company, also known as BD, is an American multinational medical technology company that manufactures and sells medical devices, instrument systems, and reagents. BD also provides consulting and analytics services in certain geographies.
Visit Website →Harvard Bioscience Inc
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services that enable fundamental research, discovery, and preclinical testing for drug development. The company is headquartered in Holliston, Massachusetts.
Compare with Other MEDICAL INSTRUMENTS & SUPPLIES Stocks
Want to dig deeper into these stocks?